Strategic Partnerships Actelion, now part of Janssen, has recently entered into strategic research collaborations with multiple organizations like Odyssey Therapeutics, Serotiny, and Brubotics. Leveraging these partnerships can lead to joint sales opportunities and access to new markets.

Expanding Product Portfolio With successful settlements and confirmed benefits of products like the bioinert YMC Accura Triart Bio C18 column, Actelion/Janssen is paving the way for the launch of new pharmaceuticals in the US and other markets. This expansion offers potential sales avenues for the company's diverse offerings.

Mentorship Program Janssen's launch of the WiSTEM2D mentorship program indicates a proactive approach towards nurturing talent, especially focusing on female leaders in healthcare. This program could attract interest from educational institutions and healthcare organizations, providing networking and sales opportunities.

Global Collaborations Partnerships with universities like the University of Science and Technology in Yemen and the Kwame Nkrumah University of Science and Technology present unique sales prospects by tapping into the academic and healthcare sectors. Collaborating on mental healthcare and therapy optimization can lead to further sales growth.

Market Positioning Actelion (Janssen) showcases financial stability with revenues in the range of $100 million to $1 billion. Leveraging this strong financial standing, the company is well-positioned to explore sales expansion opportunities, potentially competing with key players like Pfizer and Novartis in the pharmaceutical industry.